Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study

Hugo Geerts, Shaina M. Short, Athena Grant, Piet H. van der Graaf · 2026

Read Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study by Hugo Geerts, Shaina M. Short, Athena Grant, Piet H. van der Graaf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13172624.txt.

Description

Hugo Geerts and co-authors simulate anti-amyloid therapy effects on Alzheimer's markers in a 2026 study. Antibodies against amyloid may become standard care, yet practical questions persist. When to switch to maintenance therapy lacks an easy biomarker. Which patients gain most cognition is also unclear.

A validated systems pharmacology model simulated amyloid species over time. A neuronal network model of cognition was coupled to it. Ion channel effects of amyloid and tau informed the coupling. The combined model explained much variance in trial data. Seven antibodies' biomarker and rating changes were matched well. Antibody-specific marker drops needed for brain amyloid clearance were derived. Those thresholds could time the switch to maintenance dosing. Patient profiles for optimal benefit were explored in silico. The authors offer the platform for trial design questions. Fluid markers gain a mechanistic interpreter.

Catalog record

CREATORHugo Geerts, Shaina M. Short, Athena Grant, Piet H. van der Graaf
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13172624

Browse the full library · About the Tower of Babel